Skip to main content

Table 3 Incidence of uveitis with mAb and ETA, without and with adjustment for propensity score (PS)

From: Occurrence of anterior uveitis in patients with spondyloarthritis treated with tumor necrosis factor inhibitors: comparing the soluble receptor to monoclonal antibodies in a large observational cohort

  

ETA versus mAb (reference = mAb)

Qualitative analysis

Quantitative analysis

OR [95% CI]

p

RR [95% CI]

p

First year of TNF inhibitor treatment

Unadjusted for PS

0.81 [0.32, 2.03]

0.65

0.54 [0.24, 1.24]

0.15

Adjusted for PS

0.94 [0.35, 2.54]

0.90

0.62 [0.26, 1.46]

0.27

First-line TNF inhibitor

Unadjusted for PS*

1.39 [0.71, 2.72]

0.30

0.97 [0.66, 1.43]

0.89

Adjusted for PS*

1.89 [0.90, 4.01]

0.09

1.10 [0.70, 1.72]

0.68

All therapeutic lines of TNF inhibitors

Unadjusted for PS*

1.57 [0.71, 3.46]

0.27

1.01 [0.61; 1.69]

0.96

Adjusted for PS*

1.98 [0.90, 4.37]

0.08

1.21 [0.68, 2.16]

0.53

  1. OR odds ratio, RR relative risk, 95% CI 95% confidence interval
  2. *Adjusted for duration of TNF inhibitor treatment